OM
KNSA icon

Opaleye Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Opaleye Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-62,501
Closed -$1.39M – 44
2025
Q1 		$1.39M Buy
+62,501
New +$1.29M 0.31% 38
2024
Q1 		– Sell
-37,500
Closed -$640K – 57
2023
Q4 		$640K Buy
+37,500
New +$616K 0.17% 46
2022
Q3 		– Sell
-814,250
Closed -$7.89M – 47
2022
Q2 		$7.89M Sell
814,250
-298,250
-27% -$2.78M 3.56% 9
2022
Q1 		$11.1M Buy
1,112,500
+87,500
+9% +$927K 3.43% 10
2021
Q4 		$12.1M Sell
1,025,000
-285,000
-22% -$3.5M 2.56% 12
2021
Q3 		$14.9M Buy
1,310,000
+154,800
+13% +$2.02M 2.79% 11
2021
Q2 		$16.1M Buy
1,155,200
+834,274
+260% +$12.7M 2.67% 11
2021
Q1 		$5.94M Buy
320,926
+96,826
+43% +$1.98M 0.87% 34
2020
Q4 		$3.96M Sell
224,100
-113,900
-34% -$2M 0.52% 41
2020
Q3 		$8.78M Sell
338,000
-6,500
-2% -$122K 1.72% 25
2020
Q2 		$8.78M Buy
+344,500
New +$7.2M 1.77% 19

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Opaleye Management's KNSA Position: Q2 2025 in Review

Opaleye Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2025, closing a stake of 62,501 shares — an estimated $1.39M sold.

Opaleye Management first reported a position in KNSA in Q2 2020 and held it in 11 quarters. The position peaked at $16.1M in Q2 2021. 189 funds tracked by Wall St. Rank hold KNSA as of Q2 2025.

  • Opaleye Management reported no remaining Kiniksa Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Opaleye Management sold 62,501 Kiniksa Pharmaceuticals shares in Q2 2025, an estimated $1.39M.
  • Opaleye Management first reported a position in Kiniksa Pharmaceuticals in Q2 2020 and held it in 11 quarters.
  • Opaleye Management's Kiniksa Pharmaceuticals position peaked at $16.1M in Q2 2021.
  • 189 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2025.

Based on Opaleye Management's 13F filing for Q2 2025, filed 14 Aug 2025.